Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study. [electronic resource]
Producer: 20170824Description: 803-811 p. digitalISSN:- 1474-5488
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Carboplatin -- administration & dosage
- Carcinoma, Squamous Cell -- drug therapy
- Chemoradiotherapy -- adverse effects
- Deglutition Disorders -- etiology
- Disease-Free Survival
- Follow-Up Studies
- Human papillomavirus 16
- Humans
- Induction Chemotherapy -- adverse effects
- Leukopenia -- chemically induced
- Male
- Middle Aged
- Mucositis -- etiology
- Neoplasm Metastasis
- Neoplasm Recurrence, Local -- diagnosis
- Neoplasm Staging
- Neutropenia -- chemically induced
- Oropharyngeal Neoplasms -- drug therapy
- Paclitaxel -- administration & dosage
- Papillomavirus Infections -- complications
- Radiotherapy Dosage
- Response Evaluation Criteria in Solid Tumors
- Survival Rate
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.